CTC enumeration and characterization has predictive and prognostic implications in patients with metastatic breast cancer treated with exemestane plus the mTOR inhibitor everolimus

被引：0
|
作者：
Agelaki, Sofia [1 ,2 ]
Mavroudis, Dimitris [1 ,2 ]
Spiliotaki, Maria [2 ]
Politaki, Eleni [2 ]
Papadaki, Maria A. [2 ]
Apostolaki, Stella [2 ]
Nikolaou, Christos [1 ]
Georgoulias, Vassilis [1 ,2 ]
机构：
[1] Univ Hosp Heraklion, Iraklion, Greece
[2] Univ Crete, Sch Med, Lab Tumor Cell Biol, Rethimnon, Greece
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-01-13
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus
    Omarini, Claudia
    Filieri, Maria Elisabetta
    Bettelli, Stefania
    Manfredini, Samantha
    Kaleci, Shaniko
    Caprera, Cecilia
    Nasso, Cecilia
    Barbolini, Monica
    Guaitoli, Giorgia
    Moscetti, Luca
    Maiorana, Antonino
    Conte, Pier Franco
    Cascinu, Stefano
    Piacentini, Federico
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [2] Pneumocystis Jirovecii pneumonia (PJP) in metastatic breast cancer (MBC) patients (pts) treated with mTOR inhibitor everolimus (EVE) and exemestane (AI).
    Watson, Geoffrey
    Gullo, Giuseppe
    Zacchia, Alessandra
    Zanoni, Daniele
    Crown, John
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
    Okazaki, Misato
    Horimoto, Yoshiya
    Tanabe, Masahiko
    Ichikawa, Yuko
    Tokuda, Emi
    Arakawa, Atsushi
    Kobayashi, Toshiyuki
    Saito, Mitsue
    MEDICAL ONCOLOGY, 2018, 35 (04)
  • [4] Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
    Misato Okazaki
    Yoshiya Horimoto
    Masahiko Tanabe
    Yuko Ichikawa
    Emi Tokuda
    Atsushi Arakawa
    Toshiyuki Kobayashi
    Mitsue Saito
    Medical Oncology, 2018, 35
  • [5] Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus
    Filieri, M. E.
    Bettelli, S. R.
    Maiorana, A.
    Caprera, C.
    Manfredini, S.
    Caggia, F.
    Iattoni, E.
    Cascinu, S.
    Omarini, C.
    Piacentini, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy
    Cook, Madeline M.
    Al Rabadi, Luai
    Kaempf, Andy J.
    Saraceni, Megan M.
    Savin, Michael A.
    Mitri, Zahi I.
    ONCOLOGIST, 2021, 26 (02): : 101 - 106
  • [7] HEALTH-RELATED QUALITY OF LIFE (QOL) IN METASTATIC BREAST CANCER PATIENTS TREATED WITH EVEROLIMUS AND EXEMESTANE VERSUS EXEMESTANE MONOTHERAPY
    Burris, H.
    Beck, J. T.
    Rugo, H.
    Baselga, J.
    Lebrun, F.
    Taran, T.
    Bennett, L.
    Ricci, J.
    Sahmoud, T.
    Hortobagyi, G. N.
    ANNALS OF ONCOLOGY, 2012, 23 : 121 - 122
  • [8] Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting
    Generali, Daniele
    Montemurro, Filippo
    Bordonaro, Roberto
    Mafodda, Antonino
    Romito, Sante
    Michelotti, Andrea
    Piovano, Pierluigi
    Ionta, Maria Teresa
    Bighin, Claudia
    Sartori, Donata
    Frassoldati, Antonio
    Cazzaniga, Marina Elena
    Riccardi, Ferdinando
    Testore, Franco
    Vici, Patrizia
    Barone, Carlo Antonio
    Schirone, Alessio
    Piacentini, Federico
    Nole, Franco
    Molino, Annamaria
    Latini, Luciano
    Simoncini, Edda Lucia
    Roila, Fausto
    Cognetti, Francesco
    Nuzzo, Francesco
    Foglietta, Jennifer
    Minisini, Alessandro Marco
    Goffredo, Francesca
    Portera, Giuseppe
    Ascione, Gilda
    Mariani, Gabriella
    ONCOLOGIST, 2017, 22 (06): : 648 - 654
  • [9] Statin use in patients with hormone receptor-positive metastatic breast cancer treated with everolimus and exemestane
    Lee, Kyoungmin
    Noh, Eunjin
    Moon, Seok Joo
    Joo, Yoonjung Yoonie
    Kang, Eun Joo
    Seo, Jae Hong
    Park, In Hae
    CANCER MEDICINE, 2023, 12 (05): : 5461 - 5470
  • [10] Evaluation of safety and activity of everolimus plus exemestane in metastatic breast cancer: a single institution experience
    Ferrarini, I.
    Bertolini, I.
    Fancelli, S.
    De Angelis, C.
    Fontana, A.
    Salvadori, B.
    Landucci, E.
    Michelotti, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 15 - 16
12345